Tirzepatide – Dual-Action GLP-1 & GIP Agonist for Research Use
Tirzepatide is an advanced dual-receptor agonist that activates both GLP-1 and GIP pathways, offering a powerful and innovative solution for research into weight loss and metabolic health. This combination of receptor activity has demonstrated promising results in clinical studies, making Tirzepatide a valuable tool for researchers exploring next-generation therapies.
Now available in 10mg, 20mg, and 30mg concentrations, Tirzepatide allows for flexible dosing tailored to the specific requirements of your research protocol.
⸻
🚀 Key Benefits
• For Research Use Only: Not intended for human consumption or clinical use.
• Dual Mechanism of Action: Simultaneous activation of GLP-1 and GIP receptors for enhanced metabolic outcomes.
• Flexible Dosing Options: Available in 10mg, 20mg, and 30mg vials to support a range of research applications.
• Targeted Research Focus: Ideal for studies on advanced weight loss strategies, type 2 diabetes, and metabolic disorders.
• Free Injection Pen Included: Each order comes with a complimentary injection pen for added convenience in administration.
⸻
📦 Packaging & Availability
Each vial contains lyophilized peptide powder, ready for reconstitution as per your research protocol. Store in a cool, dry place. After reconstitution, refrigerate at 2–8°C.
⸻
🛒 Order Tirzepatide Today
Explore the cutting edge of metabolic research with Tirzepatide—available in 10mg, 20mg, and 30mg, each with a free injection pen included.
